PMID: 29465031Feb 22, 2018Paper

Management of cardiovascular complications secondary to medical treatment of cancer

Ugeskrift for laeger
Ann BankeMorten Schou

Abstract

As the prognoses of both heart and cancer patients have improved along with a longer life expectancy in the general population, the prevalence of both heart- and cancer diseases is increasing. Thus, a larger proportion of cancer patients will have cardiovascular co-morbidity and an increased risk of cardiovascular complications during and after cancer treatment. In this article, the current knowledge on the prevention, monitoring and treatment of cardiotoxicity induced by medical anti-cancer treatment with focus on anthracyclines, trastuzumab and 5-fluorouracil is described.

Related Concepts

Related Feeds

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.

Related Papers

Archives of Disease in Childhood
J P Hale, I J Lewis
Arquivos brasileiros de cardiologia
Aguinaldo Figueiredo Freitas, Salvador Rassi
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography
Xiaoshen Zhang, Yaoqin Yang
Cancer Control : Journal of the Moffitt Cancer Center
K J ViesonR Bradbury
© 2022 Meta ULC. All rights reserved